- Home
- CVKD vs DRIO Comparison
CVKD vs DRIO Comparison
Compare CVKD & DRIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- DRIO
- Stock Information
- Founded
- CVKD 2022
- DRIO 2011
- Country
- CVKD United States
- DRIO United States
- Employees
- CVKD N/A
- DRIO N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- DRIO Medical/Dental Instruments
- Sector
- CVKD Health Care
- DRIO Health Care
- Exchange
- CVKD Nasdaq
- DRIO Nasdaq
- Market Cap
- CVKD 26.3M
- DRIO 25.1M
- IPO Year
- CVKD 2023
- DRIO N/A
- Fundamental
- Price
- CVKD $17.04
- DRIO $0.81
- Analyst Decision
- CVKD Strong Buy
- DRIO Strong Buy
- Analyst Count
- CVKD 2
- DRIO 1
- Target Price
- CVKD $46.00
- DRIO $4.00
- AVG Volume (30 Days)
- CVKD 84.2K
- DRIO 62.2K
- Earning Date
- CVKD 11-07-2024
- DRIO 11-07-2024
- Dividend Yield
- CVKD N/A
- DRIO N/A
- EPS Growth
- CVKD N/A
- DRIO N/A
- EPS
- CVKD N/A
- DRIO N/A
- Revenue
- CVKD N/A
- DRIO $23,052,000.00
- Revenue This Year
- CVKD N/A
- DRIO $36.66
- Revenue Next Year
- CVKD N/A
- DRIO $35.35
- P/E Ratio
- CVKD N/A
- DRIO N/A
- Revenue Growth
- CVKD N/A
- DRIO N/A
- 52 Week Low
- CVKD $5.40
- DRIO $0.71
- 52 Week High
- CVKD $32.55
- DRIO $2.60
- Technical
- Relative Strength Index (RSI)
- CVKD 57.77
- DRIO 34.82
- Support Level
- CVKD $16.25
- DRIO $0.84
- Resistance Level
- CVKD $19.97
- DRIO $0.95
- Average True Range (ATR)
- CVKD 1.80
- DRIO 0.07
- MACD
- CVKD -0.04
- DRIO -0.01
- Stochastic Oscillator
- CVKD 54.70
- DRIO 7.18
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
About DRIO DarioHealth Corp.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.